Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug

Core Insights - Orion anticipates significant growth for darolutamide, a prostate cancer medication co-developed with Bayer [1] Company Summary - Orion is focused on the development and commercialization of darolutamide, indicating a strong commitment to the oncology market [1] Industry Summary - The prostate cancer treatment market is expected to expand, with darolutamide positioned as a key player due to its co-development with Bayer [1]